The US FDA has told makers of all GLP-1 drugs to add a warning about a rare eye stroke called NAION to their labels.

NAION cuts blood flow to the optic nerve. It can cause sudden, painless vision loss in one eye.

The change covers all 12 GLP-1 products on the FDA list, including Ozempic, Wegovy, Mounjaro and Zepbound.

In 126 trials with 134,253 patients, the FDA found 6.4 cases per 100,000 person-years on GLP-1 drugs, against 3.8 in comparison groups.

The FDA calls it a potential increased risk. It does not say the drugs cause the condition.

Studies disagree. One US records study found 76% higher risk, while a Cleveland Clinic study of 220,000 users found no significant rise.

Doctors should tell patients to report sudden vision changes and send suspected cases to an eye specialist the same day.

It is not a boxed warning, a recall or a ban. Eli Lilly says it is evaluating the update.

In India, GLP-1 sales reached Rs 2,333 crore in the year to August 2026, up from Rs 153 crore in 2022.

Mounjaro is now India's top-selling drug by value, with Rs 1,256 crore in sales over those 12 months.

Read the full GLP-1 eye stroke warning story on Trends News Stories.

Want health news on your phone? Follow TrendsNewsStories on WhatsApp. Tap Join WhatsApp below.